From Soil to Shelf: Teixobactin at Ten─Mechanism, SAR, and the Road to Clinical Application

Abstract

The discovery of teixobactin in 2015 was a landmark in the fight against antimicrobial resistance, introducing a novel antibiotic scaffold with a unique mechanism of action. Isolated from the previously unculturable soil bacterium Eleftheria terrae using the innovative iChip technology, teixobactin initially showed the remarkable ability to kill pathogens without apparent development of resistance. Over the past decade, intensive research has unraveled a complex mode of action: teixobactin dual-targets the essential cell wall precursors Lipid II and Lipid III, then triggers a cascade of self-assembly into amyloid-like fibrils on bacterial membranes, sequestering these precursors and lysing the cell. Commemorating its 10th anniversary, this review provides a comprehensive analysis of teixobactin’s journey. We examine key structure–activity relationships (SAR) derived from the synthesis of numerous analogs that identified critical residues and moieties required for activity and led to promising derivative compounds. At the same time, the road from soil to clinic has been marked by challenges. The very property that underlies teixobactin’s potent mechanism, its tendency to aggregate, also poses significant formulation problems, a “potency-formulation paradox.” Furthermore, the initial resistance-proof promise has been toned down by conflicting studies: some confirm an exceptionally high barrier to resistance, while others raise concerns about rapid adaptation and cross-resistance. On top of these scientific challenges are the economic and regulatory barriers that affect antibiotic development today. In sum, this review synthesizes a decade of research, framing teixobactin not only as a promising antibiotic candidate but also as an illuminating case study of the scientific, manufacturing, and economic challenges in bringing new antimicrobials to patients in the 21st century.